|
|
|
|
Home In The News |
|
In The News
| |
 |
 |
 |
 |
Researchers at Yale School of Medicine have developed a blood test with enough sensitivity and specificity to detect early stage ovarian cancer with 99 percent accuracy
Results of this new study are published in the journal Clinical Cancer Research. The results build on work done by the same Yale group in 2005 showing 95 percent effectiveness of a blood test using four proteins.
"The ability to recognize almost 100 percent of new tumors will have a major impact on the high death rates of this cancer," said Mor. "We hope this test will become the standard of care for women having routine examinations."
Epithelial ovarian cancer is the leading cause of gynecologic cancer deaths in the United States and three times more lethal than breast cancer. It is usually not diagnosed until its advanced stages and has come to be known as the "silent killer."
More >>
|
| |
 |
 |
 |
 |
Combined positron emission tomography (PET) and computed tomography (CT) scanning of patients in the early stages of ovarian cancer can enable physicians to determine whether the cancer has spread to nearby lymph nodes without having to perform surgery, according to researchers at the SNM's 55th Annual Meeting. As a result, unnecessary surgeries could be reduced, which would also lower morbidity rates and postoperative complications for ovarian cancer patients.
"Our preliminary research indicates that using PET/CT scanning in this way could greatly improve quality of life for many patients with ovarian cancer," said Luca Guerra, doctor of nuclear medicine, San Gerardo Hospital, Monza, Italy, and lead researcher of the study, 18F-FDG PET/CT Usefulness in Initial Staging of Ovarian Cancer. "PET/CT scans could allow many women to forego major abdominal surgery to determine whether their cancer has spread. It's a much safer alternative for determining the stages o
More >>
|
| |
 |
 |
 |
 |
Women's reports of persistent, recent-onset symptoms linked to ovarian cancer -- abdominal or pelvic pain, difficulty eating or feeling full quickly and abdominal bloating -- when combined with the CA125 blood test may improve the early detection of ovarian cancer by 20 percent, according to new findings by researchers at Fred Hutchinson Cancer Research Center published online in CANCER.
Research has found that when used alone, a simple four-question symptom-screening questionnaire and the CA125 ovarian-cancer blood test each detect about 60 percent of women with early-stage ovarian cancer and 80 percent of those with late-stage disease. This study found that when used together, the questionnaire and blood test may boost early-detection rates to more than 80 percent and late-stage detection rates to more than 95 percent.
More >>
|
Print This Page
|
|
|
|